Naomi Habib, MD
Critical Care Medicine · Phoenix, AZNPI 1639412034
Payments from drug & device makers
Across 504 payments — averaging $2041.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$781K
- United Therapeutics Corporation$127K
- Actelion Pharmaceuticals US, Inc.$112K
- Chiesi USA, Inc.$5K
- Inari Medical, Inc.$924
- Olympus America Inc.$305
- plus $3K from 27 others
What the payments were for
- Consulting fees$46,14315%
- Speaking & faculty fees$204,92969%
- Travel & lodging$30,44810%
- Food & beverage$16,5916%
- Education$3300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 94 | $781,388 |
| United Therapeutics Corporation | 151 | $126,852 |
| Actelion Pharmaceuticals US, Inc. | 161 | $111,754 |
| Chiesi USA, Inc. | 5 | $5,333 |
| Inari Medical, Inc. | 5 | $924 |
| Olympus America Inc. | 6 | $305 |
| AstraZeneca | 8 | $235 |
| Sandoz | 8 | $226 |
| Grifols USA, LLC | 6 | $226 |
| Grifols Shared Services North America, Inc. | 2 | $198 |
| Liquidia Technologies, Inc. | 2 | $189 |
| Amgen(2 entities) | 3 | $154 |
| Genentech USA, Inc. | 2 | $141 |
| Boehringer Ingelheim | 6 | $141 |
| GSK | 7 | $133 |
| Abiomed | 1 | $128 |
| Verona Pharma, Inc. | 4 | $115 |
| Viiv Healthcare Company | 4 | $99 |
| Insmed, Inc. | 3 | $65 |
| Sanofi | 3 | $63 |
| Johnson & Johnson(2 entities) | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| Mylan Specialty L.p. | 2 | $40 |
| Gilead | 2 | $39 |
| Philips North America LLC | 2 | $37 |
| Bayer | 1 | $33 |
| Shionogi Inc | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| AbbVie | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Pfizer | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Oxford Immunotec USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$101,584
- OPSUMIT$96,101
- TYVASO$46,870
- WINREVAIR$37,383
- REMODULIN$20,689
- ORENITRAM$4,630
- FLOWTRIEVER CATHETER, S$924
- CT THROMBECTOMY SYSTEM KIT$924
- Spiration Valve System$135
- FASENRA$125
- KRYSTEXXA$125
- NONE$116
- EVIS EXERA II ULTRASONIC BRONCHOFIBERVIDEOSCOPE$115
- Prolastin-C Liquid$112
How this compares
$1,029,084 in reported general payments places this provider in the 95th percentile of 175 critical care medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 377 | $4,763,021 |
| UptraviSelexipag | 129 | $2,805,264 |
| WinrevairSotatercept-Csrk | 137 | $1,945,662 |
| Ambrisentan | 382 | $1,465,541 |
| Tyvaso DpiTreprostinil | 55 | $1,305,878 |
| OfevNintedanib Esylate | 74 | $977,506 |
| Winrevair (2 Pack)Sotatercept-Csrk | 24 | $677,894 |
| LetairisAmbrisentan | 40 | $512,175 |
| AdempasRiociguat | 24 | $338,853 |
| OpsynviMacitentan/Tadalafil | 26 | $332,289 |
| AdcircaTadalafil | 74 | $309,409 |
| Tadalafil | 462 | $225,795 |
| Sildenafil Citrate | 118 | $112,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $79,954 |
| EliquisApixaban | 74 | $70,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $111,754 | $7,900,575532 claims |
| MerckWinrevair, Winrevair (2 Pack) | $781,388 | $2,623,556161 claims |
| Boehringer IngelheimOfev, Jardiance, Stiolto Respimat, Spiriva Respimat | $141 | $1,037,084160 claims |
| GileadLetairis | $39 | $512,17540 claims |
| BayerAdempas | $33 | $338,85324 claims |
| United Therapeutics CorporationAdcirca | $126,852 | $309,40974 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $133 | $144,299209 claims |
| PfizerEliquis | $17 | $70,35574 claims |
| AstraZenecaSymbicort | $235 | $17,07753 claims |
| Johnson & JohnsonXarelto | $59 | $13,32115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 critical care medicine providers in Arizona.
Other critical care medicine in Phoenix
- Heather PrzybylPhoenix$126K
- Syed ShahryarPhoenix$20K
- Dany BahdouchPhoenix$4K
- Alok SuranaPhoenix$4K
- Brent CutshallPhoenix$3K
- Muhammad RazaPhoenix$2K
- Abdalla FaddaPhoenix$2K
- Aysha AgarwalPhoenix$2K
- Aaron DahlPhoenix$2K
- Sara OcheltreePhoenix$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.